Edition:
India

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

15.89USD
11:41pm IST
Change (% chg)

$0.09 (+0.57%)
Prev Close
$15.80
Open
$16.08
Day's High
$16.08
Day's Low
$15.50
Volume
309,466
Avg. Vol
420,732
52-wk High
$19.36
52-wk Low
$4.52

Latest Key Developments (Source: Significant Developments)

Atara Biotherapeutics Reports Early Findings Of Potential Efficacy From Phase 1 Study Of ATA188 In Patients With Progressive Multiple Sclerosis At ECTRIMS 2019
Friday, 13 Sep 2019 

Sept 13 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS REPORTS EARLY FINDINGS OF POTENTIAL EFFICACY FROM PHASE 1 STUDY OF ATA188 IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS AT ECTRIMS 2019.ATARA BIOTHERAPEUTICS - SAFETY RESULTS SHOWED THAT ACROSS 4 PLANNED DOSE COHORTS, ATA188 WAS WELL TOLERATED IN PATIENTS WITH PROGRESSIVE FORMS OF MS.ATARA BIOTHERAPEUTICS - TO ADVANCE ATA188 FOR MS PATIENTS & PRESENTING ADDITIONAL EFFICACY AND SAFETY RESULTS FROM THIS STUDY IN 2020.  Full Article

Atara Biotherapeutics Reports Q2 Loss Per Share $1.60
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.Q2 LOSS PER SHARE $1.60.Q2 EARNINGS PER SHARE ESTIMATE $-1.50 -- REFINITIV IBES DATA.ATARA BIOTHERAPEUTICS EXPECTS NET OFFERING PROCEEDS, EXISTING CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS, TO FUND PLANNED OPERATIONS INTO 2021.  Full Article

Atara Biotherapeutics Announces Pricing Of $150 Mln Public Offering
Friday, 19 Jul 2019 

July 18 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF $150.0 MILLION PUBLIC OFFERING.ATARA BIOTHERAPEUTICS - PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 6.9 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $15.28 PER SHARE.  Full Article

Atara Biotherapeutics Announces Proposed Offering Of Common Stock
Friday, 19 Jul 2019 

July 18 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.ATARA BIOTHERAPEUTICS INC - ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $125 MILLION OF SHARES OF ITS COMMON STOCK.  Full Article

Atara Biotherapeutics Announces Collaborator Presentation Of Positive Phase 1 Clinical Results For Mesothelin-Targeted Car T Immunotherapy
Sunday, 31 Mar 2019 

March 31 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES COLLABORATOR PRESENTATION OF POSITIVE PHASE 1 CLINICAL RESULTS FOR A MESOTHELIN-TARGETED CAR T IMMUNOTHERAPY IN PATIENTS WITH ADVANCED MESOTHELIOMA.ATARA BIOTHERAPEUTICS- MESOTHELIN-TARGETED, AUTOLOGOUS CAR T ADMINISTRATION FOUND GENERALLY WELL-TOLERATED WITH NO CAR T-RELATED TOXICITIES HIGHER THAN GRADE 2.  Full Article

Atara Biotherapeutics Q4 Loss Per Share $1.75
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.Q4 LOSS PER SHARE $1.75.  Full Article

BRIEF-Atara Biotherapeutics Says First Patient Enrolled In Randomized Placebo-Controlled Study Of Allogeneic T-Cell Therapy ATA188

* ATARA BIOTHERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN RANDOMIZED PLACEBO-CONTROLLED STUDY OF ALLOGENEIC T-CELL THERAPY ATA188 IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS Source text for Eikon: Further company coverage: